Pregnancy Outcome Following Maternal Use of the New Selective Serotonin Reuptake Inhibitors

Maternal depression and child development

“…However, Kulin et al (57) did not find any increase in major fetal malformations or pregnancy-related complications in 267 women taking SSRIs compared with 267 controls. Another study (58) on 228 pregnant women taking fluoxetine showed an increase in minor perinatal complications when the medication was taken during the third trimester.…”

Therapeutic Approaches for Depression During Pregnancy and Lactation

“…According to the Swedish National Registry data [18], the intake of paroxetine during the first gestational period increases the risk of the infant developing congenital heart abnormality, so it is not recommended for use during pregnancy. Sertraline has been reported as not having increased the risk of congenital abnormality, miscarriage, and still birth [18,19]. Fluvoxamine and citalopram are Category C drugs.…”

“…Fluvoxamine has reportedly not increased the risks of congenital abnormality and miscarriage [19]. In a large-scale study on mothers and their newborn babies exposed to citalopram, the incidence of the development of major abnormalities among them was the same as that in the general population [19]. Among atypical antidepressants, buproprion and maprotiline are classified as Category B.…”

Antenatal Exposure to Selective Serotonin Reuptake Inhibitors and Duration of Gestation

“…Some, [1][2][3][4][5][6][7][8][9][10] but not all, [11][12][13][14][15][16][17] studies suggest that the use of SSRIs during pregnancy increases the risk of preterm delivery; in the positive studies, the risk appears to be approximately doubled, on average, in SSRIexposed relative to unexposed women. An important limitation of these studies is that all were observational in design.…”